RIGL · Rigel Pharmaceuticals
United States · RS rating 93 · As of 2026-11-03
| Price | 48.86 USD |
|---|---|
| 1-day change | -3.3% |
| RS rating (overall / 1M / 3M / 12M) | 93 / 64 / 90 / 86 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 53 / 77 / 67 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +827.4% |
| Sales growth Q/Q | +0.5% |
| Distance from 52-week high | +5.0% |
| Market cap (USD) | $567.7M |